How well does the MESTT correlate with CTCAE scale for the grading of dermatological toxicities associated with oral tyrosine kinase inhibitors?
BACKGROUND
Dermatological toxicities associated with tyrosine kinase inhibitors (TKIs) are commonly graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE). A new tool has been proposed by the Multinational Association for Supportive Care in Cancer (MASCC), namely the MASCC EGFRI Skin Toxicity Tool (MESTT), as a class-specific grading system. This study was designed to assess the correlation between the severity grading of the dermatological toxicities associated with TKIs using the NCI-CTCAE v4.0 and the MESTT.


METHODS
One hundred patients were interviewed at the National Cancer Centre Singapore with the criteria of being on erlotinib, gefitinib, lapatinib, sorafenib, or sunitinib over 2 weeks and manifested dermatological toxicities. Dermatological toxicities were graded using CTCAE and MESTT 1, respectively, by a single observer. Spearman's correlation test was performed on the results.


RESULTS
Sixty-five patients (65%) experienced papulopustular rash, 72 patients (72%) had pruritus, 85 patients (85%) had xerosis, 33 patients (33%) experienced nail changes, and 24 patients (24%) had alopecia. There was significant positive correlation between the two grading systems for all investigated dermatological toxicities, namely rash (r = 0.734), pruritus (r = 0.917), xerosis (r = 0.635), and paronychia (r = 0.611) at 99% confidence level.


CONCLUSIONS
Good correlation was observed between the scales, but there is a tendency for the MESTT tended to report higher toxicity grades for rash, xerosis, and paronychia. The MESTT was also found to be more useful to grade rash specific to TKIs and had similar usefulness for grading other studied toxicities.
Chan
Alexandre
A
Department of Pharmacy, Faculty of Science, National University of Singapore, 18 Science Drive 4, Singapore 117543, Republic of Singapore. phaac@nus.edu.sg
Tan
Eng Hooi
EH
D000284:Administration, Oral; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003430:Cross-Sectional Studies; D003875:Drug Eruptions / Q000145:classification / Q000209:etiology / Q000473:pathology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy; D011446:Prospective Studies; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D012720:Severity of Illness Index
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors
Crit Rev Oncol Hematol. 2008 May;66(2):155-62
18083041
J Support Oncol. 2006 May;4(5):236-8
16724647
Cancer. 2009 Mar 15;115(6):1286-99
19170238
Curr Oncol. 2009 Jan;16(1):16-26
19229368
Oncologist. 2005 May;10(5):345-56
15851793
Ann Pharmacother. 2009 Oct;43(10):1658-66
19755624
Exp Dermatol. 2008 Sep;17(9):790-2
18503553
Oncologist. 2007 May;12(5):610-21
17522250
Support Care Cancer. 2010 Apr;18(4):509-22
20145956
Clin Lung Cancer. 2006 Dec;8 Suppl 1:S15-22
17239286